Brickell Biotech

About:

Brickell Biotech is focused on the acquisition, development, and commercialization of drug therapies for the treatment of skin diseases.

Website: http://www.brickellbio.com

Top Investors: Palisade Capital Management, AMOREPACIFIC Ventures, Charlie Stiefel

Description:

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®.